The approval of T-DM1 in the mBC setting in the USA and Europe (both 2013), as well as in China (2021) and other Asian countries, was based on results from the phase III EMILIA trial of patients with HER2-positive advanced BC who received prior treatment with trastuzumab and a taxane.4 This evidence concerns the gene ERBB2 and breast cancer.